Jinsong Wu

Title: Jinsong Wu: Innovator in Tumor Necrosis Factor Receptor Research

Introduction

Jinsong Wu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of tumor necrosis factor receptor mutants. His innovative work has the potential to impact the treatment of various diseases related to TNFalpha and lymphotoxin.

Latest Patents

Jinsong Wu holds a patent for a soluble tumor necrosis factor receptor mutant. This mutant features an amino acid substitution at position 92Glu compared to the wild TNFRII. The modification enhances the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and the fusion protein that includes it are valuable for treating diseases associated with TNFalpha and lymphotoxin.

Career Highlights

Throughout his career, Jinsong Wu has worked with notable companies in the biopharmaceutical sector. He has been associated with Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co., Ltd. and Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd. His work in these organizations has contributed to advancements in therapeutic solutions.

Collaborations

Jinsong Wu has collaborated with esteemed colleagues, including Yanjun Liu and Tong Yang. These partnerships have fostered a collaborative environment that encourages innovation and research in the field.

Conclusion

Jinsong Wu's contributions to the development of tumor necrosis factor receptor mutants highlight his role as an innovator in biopharmaceutical research. His work not only advances scientific understanding but also holds promise for future therapeutic applications.